(PRWEB) February 21, 2013
Research and Markets has announced the addition of the "Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome" report to their offering.
Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacturing process, an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010.
Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.
The report, Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome has been written to support corporate strategy, new product development, business development, R&D, and brand teams through its analysis of the biologic trends being seen and the innovations taking place in this high growth market place. This report will support the corporate strategies and key decisions being made around emerging market expansion, and future opportunities, and the challenges, which exist.
Key Reasons to Purchase
Key Topics Covered:
Biologics in emerging markets - key facts
Key challenges to greater use of biologics in the emerging markets
Who are the key biologics players in emerging markets?
For more information visit http://www.researchandmarkets.com/research/4lrpxl/biologics_in_the
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716